CapsoVision, Inc. (CV)
NASDAQ:CV
Top Page
CapsoVision, Inc.
(NASDAQ:CV)
Select Model
Select Model
Rating:51Neutral
Price Target:
$6.50
▼(-50.87% Downside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by heavy ongoing losses and large cash burn despite strong revenue growth and improving operations. Technicals are supportive with positive momentum, and recent corporate updates are constructive on product development/regulatory progress, but valuation remains pressured due to negative earnings.
Positive Factors
Revenue growth & gross margins
Sustained double‑digit top‑line growth alongside stable mid‑50s gross margins indicates underlying product demand and scalable unit economics. That combination supports a path to operating leverage and gives management room to invest in trials and commercialization without immediate margin erosion.
Negative Factors
Large and persistent cash burn
Cash burn materially outpaces revenue, reflecting structural negative free cash flow and ongoing R&D and trial costs. Persistent large outflows create sustained dependence on external financing, heightening dilution and execution risk unless the company achieves material operating improvement or secures substantial additional capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & gross margins
Sustained double‑digit top‑line growth alongside stable mid‑50s gross margins indicates underlying product demand and scalable unit economics. That combination supports a path to operating leverage and gives management room to invest in trials and commercialization without immediate margin erosion.
Read all positive factors
CapsoVision, Inc. (CV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$312.24M
Dividend YieldN/A
Average Volume (3M)45.47K
Price to Earnings (P/E)―
Beta (1Y)-1.02
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees90
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.15
Shares Outstanding49,838,210
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue21.90
Enterprise Value/Gross Profit41.37
Enterprise Value/Ebitda-11.90
Forecast
1Y Price Target
$10.50Price Target Upside-20.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$19.07M
CapsoVision, Inc. Business Overview & Revenue Model
Company Description
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics...
How the Company Makes Money
CapsoVision makes money primarily by selling its capsule endoscopy products and associated systems used by healthcare providers. Key revenue streams typically include: (1) sales of ingestible imaging capsules (often the recurring consumable in a c...
CapsoVision, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 13.55M | 11.76M | 9.75M |
| Gross Profit | 7.17M | 6.38M | 5.49M |
| EBITDA | -24.95M | -19.40M | -10.96M |
| Net Income | -25.32M | -19.90M | -11.30M |
Balance Sheet | |||
| Total Assets | 18.16M | 16.80M | 21.53M |
| Cash, Cash Equivalents and Short-Term Investments | 10.11M | 9.32M | 14.56M |
| Total Debt | 887.00K | 1.24M | 1.51M |
| Total Liabilities | 4.90M | 146.31M | 131.37M |
| Stockholders Equity | 13.26M | -129.51M | -109.84M |
Cash Flow | |||
| Free Cash Flow | -22.95M | -20.24M | -11.56M |
| Operating Cash Flow | -22.86M | -20.09M | -10.80M |
| Investing Cash Flow | -90.00K | -153.00K | -754.00K |
| Financing Cash Flow | 23.60M | 15.07M | 20.53M |
CapsoVision, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $32.18B | 31.05 | 19.73% | 0.72% | 6.73% | 3.34% | |
61 Neutral | $4.14B | 77.60 | 1.52% | ― | 4.73% | ― | |
58 Neutral | $400.79M | -14.72 | -17.65% | ― | 2.73% | 87.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $312.24M | -88.75 | 105.09% | ― | ― | ― |
* Healthcare Sector Average
CV
CapsoVision, Inc.
6.14
1.74
39.55%
A
Agilent
116.92
10.74
10.12%
ANGO
AngioDynamics
10.17
0.62
6.49%
NVST
Envista Holdings
26.66
10.22
62.17%
PFSA
Profusa
1.22
-892.03
-99.86%
CapsoVision, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
CapsoVision Raises Capital and Refocuses Colon Capsule Strategy
Neutral
Mar 20, 2026
On March 16, 2026, CapsoVision, Inc. raised approximately $14 million in a private placement of 2,867,089 common shares at a 5% discount to the prior closing price, with the deal limited to accredited investors and supported by a registration righ...
Business Operations and StrategyProduct-Related Announcements
CapsoVision Amends Canon Agreement for Upgraded Image Sensors
Positive
Mar 13, 2026
On March 9, 2026, CapsoVision, Inc. amended its development agreement with Canon Inc. to increase the total fee for developing CMOS image sensor samples by $1 million, reflecting enhanced specification features and raising the remaining developmen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.